The Chemours Company reports results for the quarter ended September 30 - Earnings Summary

What happened

The Chemours Company reported quarterly adjusted earnings of 21 cents per share, up from 20 cents a year earlier but below the 27-cent average estimate from eleven analysts. Revenue rose 3% to $1.54 billion, beating the $1.53 billion analysts expected.

Confirmed

Global impact / market context

Profit per share missed what analysts expected, even though revenue beat forecasts. That gap suggests costs or other charges weighed on results. Because analysts had already cut earnings estimates sharply, the miss may reinforce caution about how reliably Chemours turns sales into profit.

Analyst inference

Analysts rate the stock a hold, with four buy ratings, seven holds and one sell. The median 12-month price target of $17.00 sits about 22.6% above the last close of $13.16, which implies analysts see modest upside from that close.

Analyst inference

What to watch

1. The mean earnings estimate from analysts fell by about 50.3% over the last three months, and four analysts cut their estimates in the last 30 days, which signals fading confidence in near-term profit. Confirmed
2. Watch whether Chemours explains what caused adjusted earnings of 21 cents per share to fall short of the 27-cent consensus, such as higher costs or one-time charges. Proposed
3. Track whether revenue growth of 3% to $1.54 billion continues while profit per share stays under pressure, since that combination can keep the stock near the hold-rated, $17.00 target range. Analyst inference

Evidence

• Original source link unavailable